Vaccination against viral hepatitis B in patients undergoing liver transplantation for hepatitis B-unassociated causes
To study efficiency of molgramostim as an adjuvant in HBV vaccination we randomized 18 pts after OLT due to non-HBV causes. Nine pts received GM-CSF (150 mcg of sc 24 h before 1st dose of vaccine). Other 9 pts received only vaccine. Both groups of pts did not differ in sex, age, immunosuppression an...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
N.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department
2018-08-01
|
| Series: | Трансплантология (Москва) |
| Subjects: | |
| Online Access: | https://www.jtransplantologiya.ru/jour/article/view/289 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | To study efficiency of molgramostim as an adjuvant in HBV vaccination we randomized 18 pts after OLT due to non-HBV causes. Nine pts received GM-CSF (150 mcg of sc 24 h before 1st dose of vaccine). Other 9 pts received only vaccine. Both groups of pts did not differ in sex, age, immunosuppression and received vaccine in double doses (40 mcg im) by similar way (0, 1 and 2 Mo). Anti-HBs titers were estimated in 3 Mo after the last dose of vaccine. High anti-HBs titer (>200 mME/ml) achieved 4 pts (44%) from the GM-CSF group and nobody from the control group (p=0.037) No serious adverse effects occurred. Conclusion: GM-CSF may be useful as an adjuvant in HBV vaccination after OLT. |
|---|---|
| ISSN: | 2074-0506 2542-0909 |